Form 4: SOPHIA GENETICS CFO Sells Shares Under 10b5-1 Plan

SOPHIA GENETICS SA reports that Chief Financial Officer George Cardoza sold 1,592 ordinary shares to cover tax withholding obligations related to vested RSUs, executed under a Rule 10b5-1 trading plan.

Summary

• George Cardoza, Chief Financial Officer of SOPHiA GENETICS SA, sold 1,592 ordinary shares on July 6, 2026.
• The sale was conducted to cover tax withholding obligations arising from the vesting of restricted stock units on July 2, 2026.
• These transactions were executed as part of a pre-established Rule 10b5-1(c) trading plan, indicating they were not discretionary.
• The shares were sold at a weighted average price of $5.2886, with individual sales ranging from $4.97 to $5.43.
• Following the transaction, Mr. Cardoza beneficially owns 309,092 ordinary shares directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While an insider sale can be a negative signal, the clear explanation of it being part of a pre-planned Rule 10b5-1(c) trading plan for tax purposes mitigates significant concern.

Positives

• The sale was executed under a Rule 10b5-1(c) trading plan, which is designed to provide an affirmative defense against allegations of insider trading.
• The sale was for the purpose of covering tax withholding obligations, a common and expected event upon the vesting of equity awards.

Negatives

• A sale of shares by a key executive, even if pre-planned, can sometimes be perceived negatively by the market.
• The weighted average sale price of $5.2886 is noted, with a range of $4.97 to $5.43, which may indicate a slight downward pressure on price during the transaction period.

Risks

• While the sale was part of a 10b5-1 plan, any significant selling by insiders can create negative sentiment if not properly contextualized.
• The company's stock performance may be influenced by the perception of insider selling, regardless of the planned nature of the transaction.

Future Outlook

No specific future outlook or guidance is provided in this Form 4 filing, which solely reports on a completed transaction.

Management Comments

• The sales were effected pursuant to a pre-established Rule 10b5-1(c) trading plan adopted by the Reporting Person and do not represent discretionary trades.
• The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Industry Context

StockSavvy.ai notes that insider sales under Rule 10b5-1 plans are common for executives to manage personal finances and tax obligations. However, the volume and timing relative to other company news can influence market perception within the competitive biotechnology and diagnostics sector.

Stakeholder Impact

• Shareholders: May interpret the sale as a minor negative signal, though mitigated by the Rule 10b5-1 plan explanation. The direct ownership of the CFO remains substantial.
• Employees: The transaction is unlikely to have a direct impact on employees, other than reinforcing the standard practice of equity award vesting and tax management.
• Creditors/Suppliers: No direct impact is anticipated from this insider transaction.

Next Steps

• No specific next steps are outlined in this filing.

Key Dates

Keywords

SOPHIA GENETICS SA, SOPH, Form 4, Insider Trading, Rule 10b5-1, George Cardoza, Chief Financial Officer, Stock Sale, Restricted Stock Units, Tax Withholding